Shares of AC Immune (ACIU) rallied 16.3% on Tuesday to close at $8.13 after the biopharma company announced partial success in its Phase 2 trial of Alzheimer's treatment. The drug, which is developed in partnership with Roche Holding (RHHBY), was successful in meeting one of the co-primary endpoints, ADAS-Cog11. Anti-tau monoclonal antibody, semorinemab, helped in reducing cognitive decline from baseline by 43.6%, compared to placebo, in people diagnosed with mild-to-moderate Alzheimer's disease. However, AC Immune’s trials failed to show success in reducing the rate of functional decline from baseline as measured by the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL).
https://www.tipranks.com/news/ac-immune-jumps-16-3-on-partial-success-in-alzheimers-drug-trial?utm_source=advfn.com&utm_medium=referral
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Roche (QX) Charts.